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Abstract
Background: Chronic inflammations, atherosclerosis and obesity, are major risk factors for cardiovascular diseases.
Immune modulation of the inflammatory response has shown promise in animal models of atherogenesis and
metabolic disease. Tableted dietary supplement, V-6, containing pooled antigens derived from pig adipose tissue
has been administered daily to 12 volunteers for 2 months.
Results: No significant changes were observed in liver ALT and AST enzymes, i.e., 28 vs 23.8 IU and 22.6 vs 24.8 IU,
with p = 0.07 and p = 0.49, respectively. Creatinine decreased; 0.88 vs 0.84 mg/dL (p = 0.05) while BUN moved
upward; 14.5 vs 17.5 mg/dL (p = 0.01), but both values remained within normal range. Blood glucose remained
within normal range; 96.1 vs 101.1 mg/dL (p = 0.04). Complete blood cell analysis has not revealed any change
except slight increase in hemoglobin; 13.13 to 13.96 g/dL (p = 0.0002); hematocrit and red blood cells count 40.3
to 42.3% (p = 0.02) and 5.15 to 5.35 × 106 cells/mm3 (p = 0.03) respectively. Blood pressure systolic and diastolic
values were not affected, i.e., 116.1 vs 116.3 (p = 0.12) and 76.8 vs 76.6 (p = 0.99). Body weight and body mass
index (BMI) remained same; 66.4 vs 66.3 kg (p = 0.47) and 25.7 vs 25.6 kg/m2 (p = 0.2). Body fat deposit indices,
such as abdomen; mid-arm; and thigh circumferences declined by 3.5 cm (p = 0.008); 1.2 cm (p = 0.004); and 3.0
cm (p = 0.0007) respectively. The total cholesterol and LDL levels did not change; 195.5 vs 195.1 (-0.2%; p = 0.8)
and 113.4 vs 120.3 (6.1%; p = 0.08) respectively. Triglycerides have been reduced but not statistically significant;
168.1 vs 118 mg/dL (-29.8%; p = 0.2). In contrast, HDL content had risen by 29.7% from 39.4 to 51.1 mg/dL in all
12 patients (p = 0.000003). TG/HDL ratio - a marker of insulin resistance - was reduced from 4.78 to 2.56 (-46.5%;
p = 0.04).
Conclusions: These results demonstrate that V-6 is safe and has a potential as an anti-atherogenic and
overweight/obesity immune intervention.
Background
Coronary heart disease (CHD) is a leading cause of
death in industrialized countries [1]. Atherosclerosis and
obesity are two principal pathological conditions that
predispose to cardiovascular disease (CVD) [2]. The
term atherosclerosis, commonly referred to as a “hard-
ening of the arteries”, is associated with the formation
of lipid-laden plaques within the wall of large arteries.
Excessive body fat accumulation characterizes over-
weight and obesity - conditions that affect more than
60% of the adult population in the United States.
Epidemiological studies have shown that high levels of
atherogenic low density lipoproteins (LDL) and trigly-
cerides (TG) along with low levels of high density lipo-
proteins (HDL) or “good cholesterol” are strongly
associated with both atherosclerosis and obesity and
consequently the risk for CHD [1,2]. The conventional
methods for controlling abnormal lipid metabolism are
through reduction of dietary intake of fats and treatment
with cholesterol and obesity-reducing drugs. The most
important class of drugs that influences hypercholester-
olemia are statins, which mainly lower the LDL choles-
terol. Nicotinic acid and fibrates can induce higher HDL
levels but may not be taken regularly because of their
side effects. The extent of beneficiary effect of diet is* Correspondence: immunitor@aol.com
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limited and reduction of cholesterol by drugs is often
associated with unwanted side effects. Similarly, the
effect of obesity drugs has been modest and the attrition
rate is an issue that remains to be solved [3]. Thus,
alternative means to prevent and/or treat atherosclerotic
and metabolic disease have to be found to satisfy the
unmet needs.
It is now generally acknowledged that atherosclerosis
is an inflammatory disease - an idea that was first
advanced by Rudolf Wirchow in 1856 [4]. Recent studies
have brought forward the notion that obesity is a
chronic inflammation caused by self-directed immune
reaction against adipose tissue [5,6]. Modulation of the
inflammatory response may represent a valuable strategy
to prevent and/or treat both atherosclerosis and obesity
[7-10]. The earliest credible attempt of immune inter-
vention has been reported in 1959 by Hungarian scien-
tists Gero et al., who immunized rabbits with
lipoproteins isolated from the serum of cockerels [11].
In 1970’s Soviet researchers proposed that atherosclero-
sis is an autoimmune disease and tolerization with low
doses of some but not all lipoprotein fractions can pre-
vent atherogenic process [12,13]. Nevertheless, the con-
cept of immune modulation of atherosclerosis has not
become fashionable in the West until 1990’s. This delay
was perhaps due to the skeptical report by Bailey et al.,
who failed to reproduce the original findings of Gero
[14]. Nevertheless, in the past 20 years many experimen-
tal approaches, especially vaccines directed against var-
ious immunogenic entities involved in lipid metabolism,
have demonstrated success in animal models [7-10].
The first human trial of atherosclerosis vaccine was
reported in 2003 by Davidson et al. [15]. While their
cholesteryl ester transfer protein (CETP) vaccine
(CETi-1) was well tolerated and anti-CETP antibodies
were induced in patients, no substantial effect on HDL
levels has been demonstrated.
If atherosclerosis and obesity are result of self-directed
autoimmunity then oral administration of autoantigens
may indeed produce the desired immune tolerance,
which could counteract the inflammatory process [16].
In this open-label, clinical study, involving 12 indivi-
duals, we have evaluated whether oral administration of
pooled antigens from adipose tissue is safe and can
favorably affect the abnormal lipid metabolism.
Results
None of the patients had reported any adverse effect
attributed to V-6 treatment, most had noted better
mood and quality of life. While subjective, these impres-
sions are corroborated by objective lab analysis results.
The serum levels of lipids such as total cholesterol,
LDL, HDL and triglycerides have been analyzed at
2 week, 1 month and 2 month intervals after first
administered dose of V-6 (Fig. 1). The total cholesterol
content has not changed from the baseline value; 195.5
vs 195.1 (p = 0.76). LDL levels fluctuated slightly
upward but results were not statistically significant, i.e.,
113.4 vs 120.3 (p = 0.08). The cholesterol to LDL ratio
has not changed considerably, i.e., 1.86 vs 1.66
(p = 0.17). In contrast, levels of HDL have increased by
29.7% from 39.4 to 51.1 mg/dL (p = 0.000003) in all 12
patients. The average/median increase in HDL at the
end of 2 months treatment was equal to 11.7/11 mg/dL
(range 5-21 mg/dL; 95% CI 8.7 - 14.6 mg/dL). This
change reflected in decrease of cholesterol to HDL ratio
by 25% from 5.17 to 3.88 (p = 0.000001). TG levels
were reduced in 8 out 12 patients with average intra-
group decrease equal to 29.8%, i.e., from 168.1 to 118
mg/dL (p = 0.24). Nevertheless, this change was not sta-
tistically significant despite the fact that average TG
decrease (-51.9%) among 8 responders has been sub-
stantial (-80.9 mg/dL; 95% CI 150.1-11.7) as opposed to
modest increase (+6.8%) in non-responders (+11.5 mg/
dL; 95% CI 8.4-31.4). This incongruity is likely to be
due to high outlier TG values, especially in patient #4,
which caused skewed and statistically non-significant
results. The removal of patient #4 outlier numbers pro-
duced mean 25.4% decrease, i.e., from 124.9 to 93.2
mg/dL and improved the probability value (p = 0.1), but
it remained insignificant. The use of repeated measure,
non-parametric Friedman test has not produced better
significance as obtained p value (0.23) was still above
significance level. Paired, two-tailed Student t-test,
which compared baseline and end-of-study outcomes of
all 12 patients produced p = 0.054, which was still
above 0.05 cut-off value. The quasi-linear regression
analysis that considers the gap between baseline and
end-of-study TG values from outliers (patients #4 and
#6) and remaining patients produced p = 0.000000004
with R-squared regression coefficient 0.89. These results
indicate that there is a significant trend supporting TG
decrease but sample size has been insufficient to make
definitive conclusion. The TG/HDL ratio, which is a
predictor of insulin resistance and CHD risk, has been
reduced by almost half (46.5%; p = 0.036) from mean
4.78 (95% CI 1.11-8.45) to 2.56 (95% CI 0.86-4.26) as
evaluated by paired Student t-test.
V-6 effect was measured for changes in body weight
and body mass index (BMI). No significant alterations
in body weight were found, with average weight prior to
and after treatment being 66.37 vs 66.28 kg (p = 0.47).
Similar, non-significant decrease was observed with
BMI, i.e., 25.7 vs 25.6 kg/m2 (p = 0.21) (Fig. 2). The
anthropometric predictors of body fat such as abdomen,
mid-arm, and thigh circumferences were evaluated by
repeated measure ANOVA (Fig. 2). Waistline decreased
in 8 out 12 individuals from average 91.54 to 88.08 cm
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(3.5 cm; p = 0.008; 95% CI 8.9-2.0 cm). The waist cir-
cumference, when stratified to 9 women, declined from
abdominal obesity defining level 88.7 cm down to 84.1
cm (4.6 cm; p = 0.001; 95% CI 2.9-12.1 cm). Mid-arm
circumference had decreased by 4% in 8 out 12 indivi-
duals from average 30.9 cm to 29.7 cm at the end of
two months (1.2 cm; p = 0.0035; 95% CI 0.14-2.6 cm).
The thigh circumference has been reduced in 10 out of
12 individuals, i.e., 56.17 at baseline vs 53.2 cm (2.96
cm; p = 0.0007; 95% CI 0.8-5.1 cm). The similarity in
outcome from all three measured sites of fat deposition
indicates that this trend is consistent and statistically
significant despite small sample size.
Pre- and post-treatment blood pressure systolic and
diastolic values were not affected significantly, i.e., 116.1
vs 116.3 (p = 0.12) and 76.8 vs 76.6 (p = 0.99). No sig-
nificant changes were observed in liver enzymes profile.
ALT and AST levels were not influenced by V-6, i.e., 28
vs 23.8 and 22.6 vs 24.8 with p values 0.07 and 0.49,
respectively. Quite contrary, patient #4 who had elevated
ALT and AST levels (96 IU and 44 IU) at baseline had
experienced liver function improvement (56 IU and 34
IU) at the end of follow-up. V-6 had no adverse effect
on kidney function. Creatinine levels appeared to
decrease; 0.88 vs 0.84 mg/dL (p = 0.048) while blood
urea nitrogen (BUN) has shown a reverse trend; 14.5 vs
17.5 mg/dL (p = 0.014). While statistically significant,
both values remained within normal ranges; 0.5-2.0 mg/
dL and 9-23 mg/dL for creatinine and BUN, respec-
tively. Blood sugar levels also remained within the nor-
mal range (70-130 mg/dL) even though a small upward
trend has been observed; 96.1 vs 101.1 (p = 0.04).
Complete blood cell (CBC) analysis has been carried
out at regular intervals to identify changes that could be
associated with V-6 therapy. Hemoglobin levels
increased slightly from 13.13 to 13.96 g/dL (p = 0.0002),
which, however, remained within normal range 12.1-17.2
g/dL. This reflected in increase of hemoglobin amount
per red blood cell (MCH) from 25.75 up to 26.5 pico-
grams/cell (p = 0.0002), but hemoglobin concentration
Figure 1 Changes in total plasma cholesterol (CH; -0.2%; p = 0.76), low density lipoproteins (LDL; +6.1%; p = 0.08), triglycerides (TG;
-29.8%; p = 0.24), and high density lipoproteins (HDL; +29.7%; p = 0.000003), resulting from oral administration of V-6 as evaluated
by repeated measure ANOVA. Individual values from each of 12 patients, collected through weeks 2, 4, and 8, are plotted and mean values
are shown in each graph in bold.
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relative to size of the cell (MCHC) has not changed
appreciably, i.e., 32.75 vs 32.92 g/dL (p = 0.18). The aver-
age red blood cell size (MCV) increased from 77.5 to
79.8 femtoliters (p = 0.0007). Hematocrit and red blood
cells count had increased, but remained within normal
range 40.3 to 42.3% (p = 0.015) and 5.15 to 5.35 × 106
cells/mm3 (p = 0.034) respectively. The number of plate-
lets has moved upward, from 244,333 to 264,166 per
mm3, but the difference was not significant (p = 0.12).
The mean white blood cells (WBC) count has not chan-
ged: 7,858 vs 7,633 cells/mm3 (p = 0.65). The percent
of leukocytes and neutrophils was not affected by V-6
therapy; 38.5% vs 36.1% (p = 0.78) and 58.5% vs 61.7%
(p = 0.44). Although pro-inflammatory eosinophils were
seen to decline from mean 4.13% down to 2.33% the sig-
nificance was not attained (p = 0.29), mainly due to the
undetectable levels of such cells at certain time-points in
5 out 12 patients.
Discussion
The Greek physician Hippocrates observed in 400 BC
that “Sudden death is more common in those who are
naturally fat than in the lean” [17]. Atherosclerosis and
obesity were initially thought as lipid-storage diseases,
but are now increasingly recognized as inflammatory
conditions, characterized by infiltration of macrophages
and T cells, which interact with one another and with
atheromas and adipocytes [5,6]. We now know that the
connections between obesity and fatty arteries are com-
plicated, but it is clear that inflammation is the underly-
ing cause for these risk factors [1-6]. Our working
hypothesis is based on assumption that chronic inflam-
mation is due to self-directed autoimmunity and thus
the induction of immune tolerance through oral delivery
of autoantigens is a logical approach to overcome both
obesity and atherosclerosis.
The seminal work of Gero et al., has laid basis to the
ground-breaking concept that modulation of the
immune system is a valid strategy to control atherogenic
dyslipidemia. While his work was met with initial skepti-
cism, many subsequent studies have confirmed the pos-
sibility of inhibiting atherosclerosis by inducing immune
response to key antigens involved in lipid metabolism.
Gero has used beta-lipoprotein, the main protein in
Figure 2 Negligible effect of daily dose of V-6 on body mass index (BMI; -0.4%; p = 0.21) as opposed to statistically significant
reduction in waist (-3.8%; p = 0.008), mid-arm (-3.9%; p = 0.004), and thigh (-5.3%; p = 0.0007) circumferences as followed through
weeks 2, 4, and 8. Individual values from each time-point for every patient are plotted and mean values are shown as bold line.
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LDL particles, as their anti-atherogenic xenoantigen.
Then, Russian and Czech investigators have demon-
strated the atheroprotective effect in a series of animal
studies by using beta- and pre-beta-lipoproteins, choles-
terol, very low density lipoproteins (VLDL), gamma-glo-
bulin, albumin, and even Candida albicans, but not LDL
[12,13,18,19]. After a period of relative inactivity a sud-
den surge of interest became apparent in 1990’s when
several groups in the USA and Western Europe have
published the potential of cholesterol, LDL, oxidized
form of LDL, beta 2-glycoprotein, heat-shock protein 65
(HSP-65), and avian herpesvirus as vaccine antigens cap-
able of preventing atherosclerosis [20-29]. More recent
studies while continuing the investigation of earlier
identified antigens [30-35] have focused on additional
targets involved in atherogenesis. These included a wide
variety of immunogens such as cholesteryl ester transfer
protein (CETP), HSP-60, tumor necrosis factor alpha
(TNF-a), IL-12, vascular endothelial growth factor
receptor 2 (VEGF), angiopoietin-2 receptor (TIE2),
CD99, phosphorylcholine, and Streptococcus pneumo-
niae [36-47]. Recently published studies of obesity vac-
cines have shown promise with ghrelin and gastric
inhibitory polypeptide (GIP) as candidate targets for
weight control [8-10]. However, while most animal stu-
dies were encouraging, so far, only one vaccine pro-
gressed into human trials but was abandoned after
phase 2 trial had shown low level (6%) increase in HDL
levels [15].
Since there is a lack of adequate immune intervention
studies in humans how our data compares with results
from cholesterol and obesity drug trials? LDL choles-
terol is the main, if not the only, lipid target in the effort
to reduce CVD morbidity and mortality [1]. Clinical and
epidemiological studies have identified HDL as more
promising target independently and inversely associated
with an increased risk of CHD [48,49]. LDL-lowering
drugs, such as niacin, fibrates, and statins, are not very
effective in raising HDL. The meta-analysis of published
trials has shown that average HDL elevation in statin
trials was 1.6 mg/dL, fibrate trials 2.6 mg/dL, and com-
binations trials of statins with niacin 12 mg/dL. In terms
of percentage, statins, fibrates, and nicotinic acid
increase HDL by 5-10%; 10%; and 20% respectively [1].
Our mean 11.7 mg/dL or 29.7% increase in HDL levels
observed in all patients compares favorably with best
results in the field, i.e., niacin and statin combination.
Long term, follow-up studies have demonstrated that
incremental HDL elevation either in absolute or percen-
tage figures can predict cardiovascular risk. Goldenberg
et al., have shown 29% risk reduction per 5 mg/dL
increment in HDL among patients with LDL levels
below 130 mg/dL [48]. In other cholesterol-reducing
drug trials for every 1% increase in HDL there was a 3%
reduction in death or myocardial infarction [49]. If these
figures are extrapolated to our findings then risk reduc-
tion of CHD due to V-6 intervention is between 68%
and 89% - a benefit that surpasses by 2-3 folds the aver-
age benefit associated with optimal LDL reduction [1].
The effect of V-6 in reducing triglycerides has been
quite substantial but due to power limitation could not
be ascertained by every statistical test we have
employed. TG/HDL ratio, especially when higher than
3.5, is a strong independent predictor for insulin resis-
tance and cardiovascular mortality [50]. At the end
of study the TG/HDL ratio has declined from 4.78 to
2.56 (p = 0.036). This change is accompanied with 25%
(p = 0.000001) decrease of cholesterol to HDL ratio - a
predictor of atherogenesis and CHD risk. High TG and
low HDL is characteristic of patients with the metabolic
syndrome, a condition strongly associated with the
development of both type 2 diabetes and CHD. V-6
reduced TG/HDL ratio below risk threshold - an obser-
vation that supports the potential role of this interven-
tion in management of type 2 diabetes mellitus. Thus,
this endpoint needs to be queried further in a larger
population of patients.
Currently approved anti-obesity drugs, orlistat, sibutra-
mine, and rimonabant show only limited efficacy and are
often associated with unpleasant side-effects, which
account for high attrition rate. Orlistat is a gastric lipase
inhibitor, sibutramine is a noradrenaline/serotonin reup-
take blocker, and rimonabant is an endocannabinoid
CB1 receptor antagonist. The meta-analysis of data from
obesity drug trials, which included waist circumference
as an endpoint, indicates that orlistat therapy reduced
WC by 2.06 cm (95% CI 1.3-2.9); sibutramine by 3.99 cm
(95% CI 3.3-4.7); and rimonabant by 3.89 cm (95% CI
3.3- 4.5) [3]. Our waistline results are comparable to the
outcome from obesity drugs since mean WC reduction
was 3.5 cm (95% CI 8.9-2.0 cm). Other anthropometric
predictors of body fat, arm and thigh circumference, had
declined as well. It also needs to be kept in mind that in
obesity drug trials patients were commonly subjected to
low-calorie diet, exercise, and behavioral modification in
addition to drug intervention. In our group none of the
patients had changed their usual diet, quite contrary, all
patients, except one (#4), had reported increased appetite
and food intake. This perhaps explains why there were
no significant changes in body weight and BMI.
A substantial body of evidence exists which indicates
that dietary magnesium can influence atherogenesis
through reduction in cholesterol, LDL, and TG levels
[51-53]. At the same time, a marginal increase in HDL
levels (2.5 mg/dL) has been reported [53,54]. The sum-
mary of clinical outcomes can be found in the review
paper published by Rosanoff and Seelig in which they
indicated that magnesium supplements can lower CH,
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LDL, and TG by 6-23%, 10-18%, and 10-42% respec-
tively and increase HDL by 4-11% [55]. To the best of
our knowledge there is no published evidence that mag-
nesium alone can increase HDL levels by ~30% or ~12
mg/dL or reduce abdominal fat in a statistically signifi-
cant manner. As magnesium is the carrier of adipose-
derived antigens in V-6 tablet, one may argue that our
results are due to non-specific magnesium supplementa-
tion. However, it is unlikely that magnesium alone can
augment HDL and decrease fat deposit indices. If this
was true, we would expect much greater effect on CH
and LDL levels than on HDL. Nevertheless, a placebo
study employing the same dose of magnesium as in V-6
tablets needs to be conducted to rule out this possibility.
Our findings indicate that V-6 is safe and despite
small sample size had significantly increased HDL levels
and reduced obesity indices. None of the patients
reported any unpleasant side-effects or feelings. Quite
contrary they were highly satisfied with V-6 treatment -
these impressions, however, can be dismissed as subjec-
tive. Nevertheless, none of the measured safety para-
meters such as kidney and liver functions, blood
pressure, glucose levels, and CBC results have been
affected in any appreciable manner. CBC analysis has
not revealed any noticeable changes in blood picture
except statistically significant increase in hemoglobin,
hematocrit and erythrocyte levels albeit within normal
range. Since levels of hemoglobin below 13 g/dL are
strongly associated with higher risk of coronary artery
disease this finding might be interpreted as a beneficial
effect resulting from V-6 administration [56].
The magnitude of clinical response to V-6 was com-
parable to the results obtained in clinical trials of cho-
lesterol and obesity drugs. This is the first observation
whereby both cardiovascular risk factors were affected
by a single immune intervention. What is the mechan-
ism of V-6 action? Prior atherosclerosis vaccine studies
have been quite consistent that small rather than large
doses of an antigen, as well mucosal (oral or intranasal)
route of administration were more effective in achieving
the anti-atherogenic effect. These studies point toward
the phenomenon of immune tolerance - a concept we
have adopted for development of oral immunomodula-
tors for autoimmune diseases such as AIDS and viral
hepatitis B and C. These immune interventions have
shown excellent safety profile and high response rates in
several clinical trials we have conducted over the last
ten years [57,58]. The oral administration of pooled pro-
tein fraction derived from adipocytes is likely to induce
tolerance to autoantigens involved in lipid metabolism.
However, the phenomenon of immune tolerance, which
has been discovered more than 100 years ago, still has
not been studied well enough to make any authoritative
statement in regard to the mechanism of action [16].
Conclusions
Despite its origin from adipose tissue of pigs, V-6 pro-
duces an effect that is opposite to changes in lipid pro-
file resulting from pork fat-based diet [59]. Except
anecdotal evidence in alternative diet recipes we are not
aware of any credible evidence that eating lard can
reduce the risk of heart disease or make us slimmer
[60]. On the other hand, animal fat is commonly used
in folk medicine for treatment of rheumatism, asthma,
and inflammation [61]. The role of inflammation in
chronic metabolic disorders such as obesity, type 2 dia-
betes and CVD is now widely appreciated [1-6]. We are
thus at the crossroads between conventional wisdoms
and it is clear that further studies are needed to identify
the key elements involved in the immune regulation of
inflammatory reaction associated with metabolic disor-
ders. The next study will address the immune correlates
of V-6 action and seek placebo-controlled confirmation
to our preliminary findings in a larger population of
patients for an extended period of time.
Materials and methods
Subjects
The study involved 9 females and 3 males, all of Asian
origin, aged between 22 and 79, with mean/median age
39.8/38 years. The baseline mean body mass index
(BMI) was 25.7 kg/m2- reflective of higher than normal
percentage of body fat - and which places them in over-
weight category among Asians [1]. Mean waist circum-
ference (WC) in males (97.3 cm) and females (88.7) was
above abdominal obesity threshold 90 cm and 80 cm
respectively. The baseline HDL cholesterol levels were
39.4 mg/dL which is below 40 mg/dL cut-off normal
value. The triglyceride (TG) entry levels were above nor-
mal 150 mg/dL, i.e., 168.1 mg/dL. Total cholesterol
plasma content was within 200 mg/dL upper limit and
LDL content was also within normal range 62-130 mg/
dL. Mean systolic and diastolic blood pressure values
were also within normal range, i.e., 116.1 and 76.8. Base-
line blood glucose content 96.1 mg/dL was normal.
Briefly, except normal baseline blood pressure and glu-
cose our patients were overweight or obese and at
increased risk of CVD, since they had abnormal baseline
BMI, WC, TG, and HDL. Patients consented to receive
twice-daily dose of two V-6 pills for two months and be
subjected to routine laboratory and physical check-ups
at 0.5, 1, and 2 month intervals.
Lab analyzes
The peripheral blood samples were drawn and sent to a
commercial laboratory for complete CBC and standard
biochemistry tests including liver, kidney and lipid pro-
file tests.
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Anthropometric measures of adiposity
Mid-arm, abdominal and thigh diameters were mea-
sured with a flexible, non-elastic measuring tape at base-
line and at 2, 4, and 8 weeks intervals.
V-6 Immunitor
V-6 is an oral tablet preparation of specially processed
pig adipose tissue (fat cells) and is currently approved as
a dietary supplement. The tissue was hydrolyzed and
protein fraction was precipitated on a magnesium car-
rier according to proprietary process, which is a modifi-
cation of earlier published method [16].
Statistical analysis
Obtained data from study patients analyzed at 2, 4, and
8 week intervals has been analyzed using repeated mea-
sure ANOVA test (STATMOST, Dataxiom, Los
Angeles, CA). Where appropriate, basic parametric and
non-parametric tests were utilized. The probability
values for all results were considered significant at p ≤
0.05.
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